Company Information

    Singlera Genomics was founded on July 2014. The company is based in La Jolla, CA, USA . The number of employees in Singlera Genomics is less than 50. Singlera genomics is a fast growing company focusing on non-invasive genetic testing.

    Here is how Singlera Genomics describes itself: "Singlera Genomics - The future of cancer testing today from ctmDNA (circulating tumor methylated DNA)"
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Singlera Genomics has received 3 rounds of venture funding. The total funding amount is around $230M. Last venture funding round was $150M, announced on December, 2020.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Singlera Genomics - Blog

                          • The origin of the FDA and the Elixir Sulfanilamide disaster of 1937

                          • The origin of the FDA and the Elixir Sulfanilamide disaster of 1937 Safe and effective means just that to the Food and Drug Administration A bottle of the Elixir of Sulfanilamide The Pure Food and Drug Act of 1906 The early 1990’s was the age of the Progressive Era, and one key piece [...]
                          • For colorectal cancer, the only good screening test is one that is taken

                          • For colorectal cancer, the only good screening test is one that is taken Tests for detecting hidden (“occult”) blood in stool is widely available Screenshot from USPSTF CRC screening video We have discussed before the challenge of raising colorectal cancer screening rates, and the fact that there are many options in addition to [...]
                          • The high standard of reimbursed diagnostic tests

                          • The high standard of reimbursed diagnostic tests The difference between the standards of the FDA and CMS Figure from NAMSA CMS Reimbursement Webinar For a diagnostic test to get the imprimatur of FDA approval, the manufacturer has to cross a number of hurdles. Last week, the IVD consultancy NAMSA gave a web presentation [...]
                          • Calculating the odds of undetected colorectal cancer

                          • Calculating the odds of undetected colorectal cancer In a group of 200 adults aged 50 to 75, what are the chances of finding someone with undetected CRC? Many take chances with their health, in particular CRC screening The unscreened population for colorectal cancer is large. According to Exact Sciences (the manufacturer of the [...]
                          • DNA Methylation Biomarkers for Cancer – a Measurement Challenge

                          • DNA Methylation Biomarkers for Cancer – a Measurement Challenge Although studied for decades, the study of methylated cytosine DNA residues is not a trivial task for clinical in vitro diagnostics The challenge of methylation analysis in clinical diagnostics In the world of diagnostics, the measurement of biological analytes for clinical use trace its [...]
                          • Theranos, the FDA, and the Laboratory-Developed Test (LDT) loophole

                          • Cover of Forbes 400 Sept 2015 issue: "The Freshman: Elizabeth Holmes leads the class of 2014" Theranos, the FDA, and the Laboratory-Developed Test (LDT) loophole How could Theranos get away with fraud for such a long time? The American television news broadcaster ABC has produced an excellent six-part audio podcast called “The Dropout” [...]

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *